• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Meredith M. Regan, ScD


  • Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, .Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer.N Engl J Med. 2014 Jun 1.
  • Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR, Regan MM, Chipman JJ, Crociani CM, Sandler HM, Sanda MG, Hamstra DA.Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.Cancer. 2014 Apr 1;120(7):1076-82.
  • Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P, .Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.J Urol. 2014 Mar;191(3):638-45.
  • Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA, , .Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.Breast. 2013 Dec;22(6):1094-100.
  • Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS.A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.J Immunother.;36(9):490-5.
  • Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A.TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.Future Oncol. 2013 Oct;9(10):1477-87.
  • Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C.Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.Journal of the National Cancer Institute. 2013 Sep 4;105(17):1332-4.
  • Rojan A, Funches R, Regan MM, Gulley JL, Bubley GJ.Dramatic and prolonged PSA response after retreatment with a PSA vaccine.Clin Genitourin Cancer. 2013 Sep;11(3):362-4.
  • Giobbie-Hurder A, Gelber RD, Regan MM.Challenges of guarantee-time bias.J Clin Oncol. 2013 Aug 10;31(23):2963-9.
  • Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE.Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response.PLoS ONE. 2013;8(5):e64225.
  • Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U, .Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.Lancet Oncol. 2013 Apr;14(4):297-305.
  • Crivellari D, Gray KP, Dellapasqua S, Puglisi F, Ribi K, Price KN, Láng I, Gianni L, Spazzapan S, Pinotti G, Lüthi JM, Gelber RD, Regan MM, Colleoni M, Castiglione-Gertsch M, Maibach R, Rabaglio M, Coates AS, Goldhirsch A.Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial.Breast. 2013 Apr;22(2):130-7.
  • Wang H, He L, Ma F, Regan MM, Balk SP, Richardson AL, Yuan X.SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.J Biol Chem. 2013 Mar 1;288(9):6478-87.
  • Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK.External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.Lancet Oncol. 2013 Feb;14(2):141-8.
  • Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT.Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.J Clin Oncol. 2012 Nov 10;30(32):3967-75.
  • Coates AS, Millar EK, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, Gusterson B, Musgrove EA, Sutherland RL.Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.Breast Cancer Res. 2012 Nov 5;14(6):R143.
  • Kazer MW, Bailey Jr DE, Chipman J, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn RL, Crociani C, Sanda MG, .Uncertainty and perception of danger among patients undergoing treatment for prostate cancer.BJU Int. 2012 Sep 18.
  • Dellapasqua S, Bagnardi V, Regan MM, Rotmensz N, Mastropasqua MG, Viale G, Maiorano E, Price KN, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Colleoni M.A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.Breast. 2012 Oct;21(5):621-8.
  • Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnaiyan AM, Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT, Scherr DS, Sanda MA, Bartsch G, Lee C, Klocker H, Rubin MA.Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6686-91.
  • Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G, .CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial.Journal of the National Cancer Institute. 2012 Mar 21;104(6):441-451.
  • Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B, , .Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.Lancet Oncol. 2011 Nov;12(12):1101-8.
  • Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG.Selective detection of histologically aggressive prostate cancer: An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.Cancer. 2011 Oct 17.
  • Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME.Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer.Clin Genitourin Cancer. 2011 Sep 27.
  • Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG.Prediction of erectile function following treatment for prostate cancer.JAMA. 2011 Sep 21;306(11):1205-14.
  • Sun T, Oh WK, Jacobus S, Regan MM, Pomerantz M, Freedman ML, Lee GS, Kantoff PW.The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness.Cancer Prev Res (Phila Pa). 2011 Sep 7.
  • Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS, .The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.Breast Cancer Res Treat. 2011 Sep 4.
  • Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.Urol Oncol. 2011 May 19.
  • Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW.SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.J Clin Oncol. 2011 Jun 20;29(18):2565-73.
  • Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD, .Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Breast Cancer Res. 2011 May 26;13(3):209.
  • Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A.Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study.J Clin Oncol. 2011 Mar 20;29(9):1117-24.
  • Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK.Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.BJU Int. 2011 Mar 16.
  • Pomerantz M, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML.Association of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality.Cancer Prev Res (Phila Pa). 2011 Mar 2.
  • Viale G, Regan MM, Dell'orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, Macgrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS, .Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Ann Oncol. 2011 Feb 18.
  • Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX.Ann Oncol. 2011 Jan 31.
  • San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.J Urol. 2011 Feb;185(2):471-6.
  • Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM.Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.BJU Int. 2011 Jan;107(1):126-134.
  • Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S.Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article.J Neurosurg Spine. 2010 Dec;13(6):789-94.
  • Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML.Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.PLoS Genet. 2010;6(11):e1001204.
  • Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A.Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.Cancer. 2010 Sep 22.
  • Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S.Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.BJU Int. 2010 Sep;106(6):772-8.
  • Kamo N, Dandapani SV, Miksad RA, Houlihan MJ, Kaplan I, Regan M, Greenfield TK, Sanda MG.Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet.Ann Oncol. 2010 Aug 17.
  • Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.J Clin Oncol. 2010 Jun 20;28(18):2966-73.
  • McDermott DF, Ghebremichael M, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP, French M, Regan MM, Atkins MB.The high-dose aldesleukin (HD IL-2) "Select" Trial in patients with metastatic renal cell carcinoma (mRCC).Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings.;28(15S):345s.
  • Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE.Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.BJU Int. 2010 May;105(10):1392-6.
  • Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A, Macconaill L, Coetzee GA, Regan MM, Freedman ML.8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.Proc Natl Acad Sci U S A. 2010 May 25;107(21):9742-6.
  • Maiorano E,Regan MM,Viale G,Mastropasqua MG,Colleoni M,Castiglione-Gertsch M,Price KN,Gelber RD,Goldhirsch A,Coates AS.Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.Breast Cancer Res Treat. 2010 May;121(1):211-8.
  • Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK.Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.Ann Oncol. 2010 Feb;21(2):312-8.
  • Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK.Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol. 2009 Dec 1;27(34):5794-9.
  • Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.Clin Cancer Res. 2009 Nov 15;15(22):7099-105.
  • Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG.Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.J Urol. 2009 Dec;182(6):2653-8.
  • Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.Urology. 2009 Nov;74(5):1156-61.
  • , Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS.Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.N Engl J Med. 2009 Aug 20;361(8):766-76.
  • Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW.Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.J Clin Oncol. 2009 Aug 1;27(22):3577-83.
  • Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML.The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.Nat Genet. 2009 Aug;41(8):882-4.
  • Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M.Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.Cell. 2009 Jul 23;138(2):245-56.
  • Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.Clin Cancer Res. 2009 Jul 15;15(14):4706-11.
  • Regan MM.Statistical issues and challenges.Cancer Treat Res. 2009;151:77-90. Review.
  • Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML.Evaluation of the 8q24 prostate cancer risk locus and MYC expression.Cancer Res. 2009 Jul 1;69(13):5568-74.
  • Schor-Bardach R,Alsop DC,Pedrosa I,Solazzo SA,Wang X,Marquis RP,Atkins MB,Regan M,Signoretti S,Lenkinski RE,Goldberg SN.Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?.Radiology. 2009 Jun;251(3):731-42.
  • Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S.Treatment selection for patients with metastatic renal cell carcinoma.Cancer. 2009 May 15;115(10 Suppl):2327-33. Review.
  • Cho DC,Puzanov I,Regan MM,Schwarzberg T,Seery V,Lee MY,Liu V,Bhatt R,Koon H,Mier JW,Sosman JA,Atkins MB,McDermott DF.Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.J Immunother. 2009 Feb-Mar;32(2):181-5.
  • Krzyzanowska MK,Regan MM,Powell M,Earle CC,Weeks JC.Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.J Am Coll Surg. 2009 Feb;208(2):202-9.
  • Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK.Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.Cancer. 2009 Mar 1;115(5):981-7.
  • Sher DJ,Mantzoros C,Jacobus S,Regan MM,Lee GS,Oh WK.Absence of relationship between steroid hormone levels and prostate cancer tumor grade.Urology. 2009 Feb;73(2):356-61; discussion 361-2.
  • Keating NL,Stoeckert KA,Regan MM,DiGianni L,Garber JE.Physicians' experiences with BRCA1/2 testing in community settings.J Clin Oncol. 2008 Dec 10;26(35):5789-96.
  • Viale G,Giobbie-Hurder A,Regan MM,Coates AS,Mastropasqua MG,Dell'Orto P,Maiorano E,MacGrogan G,Braye SG,Ohlschlegel C,Neven P,Orosz Z,Olszewski WP,Knox F,Thurlimann B,Price KN,Castiglione-Gertsch M,Gelber RD,Gusterson BA,Goldhirsch A.Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.J Clin Oncol. 2008 Dec 1;26(34):5569-75.
  • Haram KM,Peltier HJ,Lu B,Bhasin M,Otu HH,Choy B,Regan M,Libermann TA,Latham GJ,Sanda MG,Arredouani MS.Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.Prostate. 2008 Oct 1;68(14):1517-30.
  • Sher DJ,Oh WK,Jacobus S,Regan MM,Lee GS,Mantzoros C.Relationship between serum adiponectin and prostate cancer grade.Prostate. 2008 Oct 1;68(14):1592-8.
  • Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD.Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?.Ann Oncol. 2008 Jul;19(7):1231-41.
  • Signoretti S,Regan M,Atkins M.Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.BJU Int. 2008 Jun;101 Suppl 4:31-5. Review.
  • Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.Prostate specific antigen working group guidelines on prostate specific antigen doubling time.J Urol. 2008 Jun;179(6):2181-6.
  • Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.J Clin Oncol. 2008 Mar 20;26(9):1404-10.
  • Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.Cancer. 2008 Mar 15;112(6):1247-53.
  • Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.J Clin Oncol. 2008 Feb 20;26(6):842-7.
  • Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G.p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.Ann Oncol. 2008 Apr;19(4):660-8.
  • Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS.Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Journal of the National Cancer Institute. 2008 Feb 6;100(3):207-12.
  • Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.BJU Int. 2008 Feb;101(3):308-12.
  • Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Mery E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thurlimann B, Coates AS, Viale G.Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.Lancet Oncol. 2008 Jan;9(1):23-8.
  • Xie W, Nakabayashi M, Regan MM, Oh WK.Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.Cancer. 2007 Dec 15;110(12):2709-15.
  • Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M.Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.Clin Genitourin Cancer. 2007 Sep;5(6):379-85.
  • Daskivich TJ, Regan MM, Oh WK.Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.Urology. 2007 Sep;70(3):527-31.
  • Regan MM, Gelber RD.Using clinical trial data to tailor adjuvant treatments for individual patients.Breast. 2007 Dec;16 Suppl 2:S98-104.
  • Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.J Clin Oncol. 2007 Sep 1;25(25):3846-52.
  • Hakime A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN.Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.Radiology. 2007 Aug;244(2):464-70.
  • Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK.Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer.Cancer J. 2007 March/April;13(2):125-129.
  • Cho D, Signoretti S, Regan M, Mier JW, Atkins MB.The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s. Review.
  • Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E.Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.Psychooncology. 2007 Oct;16(10):895-903.
  • Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.J Clin Oncol. 2006 Dec 1;24(34):5408-13.
  • Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B,.Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.Journal of the National Cancer Institute. 2006 Nov 1;98(21):1571-81.
  • Daskivich TJ, Regan MM, Oh WK.Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.J Urol. 2006 Nov;176(5):1927-37. Review.
  • McDermott DF, Regan MM, Atkins MB.Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.Clin Genitourin Cancer. 2006 Sep;5(2):114-9. Review.
  • Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M, Regan M, Kaelin WG.Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.EMBO J. 2006 Oct 4;25(19):4650-62.
  • Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK.Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.Cancer. 2006 Sep 1;107(5):975-81.
  • Kornblith AB, Regan MM, Kim Y, Greer G, Parker B, Bennett S, Winer E.Cancer-related communication between female patients and male partners scale: a pilot study.Psychooncology. 2006 Sep;15(9):780-94.
  • Ford BM, Evans JS, Stoffel EM, Balmaa J, Regan MM, Syngal S.Factors associated with enrollment in cancer genetics research.Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1355-9.
  • Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN.Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.Radiology. 2006 Jul;240(1):82-9.
  • San Francisco IF, Regan MM, Dewolf WC, Olumi AF.Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.J Urol. 2006 Apr;175(4):1341-5; discussion 1345-6.
  • Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK.Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.BJU Int. 2005 Oct;96(6):783-6.
  • Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S.Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.Clin Cancer Res. 2005 May 15;11(10):3714-21.
  • McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.J Clin Oncol. 2005 Jan 1;23(1):133-41.
  • Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM.Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.J Clin Oncol. 2004 Dec 15;22(24):4951-7.
  • Atkins MB, Regan M, McDermott D.Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6342S-6S.
  • Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK.Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.Ann Oncol. 2004 Jun;15(6):974-8.
  • San Francisco IF, Regan MM, Olumi AF, DeWolf WC.Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.J Urol. 2004 Apr;171(4):1492-9.
  • George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ.Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.Urology. 2004 Feb;63(2):327-32.
  • San Francisco IF, Olumi AF, Yoon JH, Regan MM, DeWolf WC.Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy.BJU Int. 2003 Dec;92(9):924-8.
  • Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.Clin Cancer Res. 2003 Aug 15;9(9):3282-7.
  • Oh WK, Tully P, Kantoff PW, Regan MM.Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma.Cancer. 2003 May 1;97(9):2171-9.
  • Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C.Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.J Urol. 2002 Nov;168(5):2249-52.
  • Parker RA, Regan MM, Reimann KA.Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics.J Virol. 2001 Nov;75(22):11234-8.
  • Regan MM, Catalano PJ.Likelihood models for clustered binary and continuous outcomes: application to developmental toxicology.Biometrics. 1999 Sep;55(3):760-8.